Skip to main content
ZYUS Life Sciences Corporation logo

ZYUS Life Sciences Corporation — Investor Relations & Filings

Ticker · ZYUS ISIN · CA9899601095 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 299 across all filing types
Latest filing 2025-11-26 Regulatory Filings
Country CA Canada
Listing TSXV ZYUS

About ZYUS Life Sciences Corporation

https://www.zyus.com/

ZYUS Life Sciences Corporation is a clinical-stage life sciences company dedicated to the development and commercialization of novel, non-opioid pharmaceutical drug candidates. The company focuses on proprietary cannabinoid-based therapeutics, or phyto-therapeutics, targeting the treatment of chronic and neuropathic pain. ZYUS's vision is to redefine the standard of care in pain management by developing evidence-based alternatives to conventional treatments, including opioids and NSAIDs. The core business involves advancing these drug product candidates through clinical trials, exemplified by the ongoing Phase 2a UTOPIA-1 trial evaluating a novel non-opioid pain drug.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2025-11-26 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2025-11-13 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release from ZYUS Life Sciences Corporation announcing the closing of a private placement (unit offering) and the issuance of warrants related to loan agreements. This falls under the category of capital raising and financing activities. While it mentions share issuance, the primary focus is the financing update (private placement and loan-related warrants), making 'CAP' the most accurate classification.
2025-11-07 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 91% confidence The document is a Loan Agreement between ZYUS Life Sciences Inc. and a lender detailing the principal amount, interest rate, security, maturity, and issuance of warrants as part of the financing. It is not an earnings release, annual report, or governance document, but a direct financing instrument outlining capital raising terms. This aligns with the Capital/Financing Update category (CAP).
2025-10-29 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 85% confidence The document is a standalone loan agreement between ZYUS Life Sciences Inc. and a lender, outlining the terms of a C$500,000 financing facility, interest, security, and warrant issuance. This is a detailed financing arrangement rather than an annual or interim report, earnings release, or regulatory announcement. It reflects a capital transaction (debt financing) by the company, fitting the definition of a Capital/Financing Update (CAP).
2025-10-29 English
Other material contracts - English.pdf
Capital/Financing Update Classification · 85% confidence The document is not an annual or interim report, earnings release, or regulatory filing but rather a contractual amendment to a promissory note (debt instrument) between ZYUS Life Sciences Inc. and a lender. It amends the maturity date, interest payment terms, and includes the issuance of warrants, representing a change in the company’s financing arrangements and capital structure. This aligns with the “Capital/Financing Update (CAP)” category.
2025-10-29 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.